Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome
Status:
Completed
Trial end date:
2020-02-14
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to
assess the safety, efficacy, tolerability and steady-state plasma trough concentration of
flexible-dosed aripiprazole once-daily administration in children and adolescents with
Tourette's syndrome. A total of around 120 subjects will be randomized to aripiprazole (2~20
mg) or placebo in a 1:1 ratio (approximately 60 subjects in each group), for treatment of 8
weeks.